Gay Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2007
- Open Charges ₹ 0.80 M
About Gay Pharmaceuticals
Gay Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 March 1995 and has a history of 29 years and ten months. Its registered office is in Meerut, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2007. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹0.80 M.
Hari Vidyarthi and Ashok Agarwal serve as directors at the Company.
Company Details
-
Location
Meerut, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231UP1995PTC017719
-
Company No.
017719
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Mar 1995
-
Date of AGM
29 Sep 2007
-
Date of Balance Sheet
31 Mar 2007
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Gay Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hari Vidyarthi
|
Director | 20-Mar-1995 | Current |
|
Ashok Agarwal
|
Director | 20-Mar-1995 | Current |
Financial Performance of Gay Pharmaceuticals.
Enhance accessibility to Gay Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gay Pharmaceuticals?
Unlock access to Gay Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.80 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Feb 2001 | Syndicate Bank | ₹0.20 M | Open |
| 24 Jan 2000 | Syndicate Bank | ₹0.30 M | Open |
| 24 Jan 2000 | Syndicate Bank | ₹0.30 M | Open |
How Many Employees Work at Gay Pharmaceuticals?
Unlock and access historical data on people associated with Gay Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gay Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gay Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.